Retatrutide
$Late-stage investigational triple agonist
Retatrutide activates GLP-1, GIP, and glucagon receptors. The glucagon component is the key differentiator from tirzepatide and may contribute to greater energy-expenditure and liver-fat effects, but it may also change tolerability.
The evidence is strong for an investigational compound but not the same as an approved product. Phase 2 results are impressive, while Phase 3 and final labeling determine the real risk-benefit profile. Don't treat gray-market retatrutide as equivalent to clinical-trial retatrutide.
Compare trial dose, titration speed, GI events, heart rate, dysesthesia, gallbladder/pancreatic signals, and lean-mass preservation.
Classification details
- Developed by Eli Lilly under the code LY3437943, retatrutide is a single synthetic peptide (not a combination of drugs), engineered so one molecule activates three receptors at once.
- First-in-class “triple G” agonist: it targets the GLP-1, GIP, and glucagon receptors together, and is the first such tri-agonist to reach Phase 3 development.
- Long-acting by design: an albumin-binding fatty-acid chain extends its half-life to about six days, supporting once-weekly subcutaneous dosing (see Section 5).
- Class & status: an investigational incretin/glucagon receptor agonist (metabolic). It is not an FDA-approved drug as of this edition and has no approved label.
- Studied for obesity, obesity with knee osteoarthritis (TRIUMPH program), type 2 diabetes, and metabolic-associated steatotic liver disease (MASLD).
- Retatrutide is an investigational triple agonist at GIP, GLP-1, and glucagon receptors. It is distinct from semaglutide and tirzepatide rather than simply a stronger GLP-1.
One molecule, three receptor “arms,” all class B, Gs-coupled GPCRs that signal through cAMP:
- GLP-1 receptor: glucose-dependent insulin release, hypothalamic satiety, and slowed gastric emptying, the appetite-and-intake arm shared with semaglutide.
- GIP receptor: adds a β-cell insulin response and adipose nutrient handling, and is thought to help blunt the nausea of GLP-1 activation, the same arm tirzepatide adds.
- Glucagon receptor, the differentiator: raises energy expenditure and drives hepatic fat oxidation/lipolysis, which underlies both the larger weight loss and the marked liver-fat reduction not seen with dual agonists.
- The balancing act: glucagon on its own would raise hepatic glucose output, so the GLP-1/GIP insulin arms must offset it. In trials net glucose control still improved. The glucagon arm also helps explain the dose-dependent rise in heart rate (Section 7).
- Its profile combines incretin satiety/glucose effects with glucagon-receptor activity that may increase energy expenditure and hepatic/metabolic effects. That broader mechanism may also broaden tolerability and monitoring issues.